

CITATION REPORT

List of articles citing

Norepinephrine deficiency in Parkinson's disease: the case for noradrenergic enhancement

DOI: 10.1002/mds.26048

Movement Disorders, 2014, 29, 1710-9.

Source: <https://exaly.com/paper-pdf/59256343/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
160	Apathy and noradrenaline: silent partners to mild cognitive impairment in Parkinson's disease?. <i>Current Opinion in Neurology</i> , 2015 , 28, 344-50	7.1	16
159	The treatment of mild cognitive impairment associated with Parkinson's disease. <i>Movement Disorders</i> , 2015 , 30, 881-2	7	3
158	Relevance of chronic stress and the two faces of microglia in Parkinson's disease. 2015 , 9, 312		30
157	Meeting commentary--"Parkinson's disease: From patient to product". 2015 , 494, 167-71		1
156	Restoring Spinal Noradrenergic Inhibitory Tone Attenuates Pain Hypersensitivity in a Rat Model of Parkinson's Disease. 2016 , 2016, 6383240		12
155	Freezing of Gait in Parkinson's Disease Is Associated with Reduced 6-[(18)F]Fluoro-l-m-tyrosine Uptake in the Locus Coeruleus. 2016 , 2016, 5430920		11
154	Dysautonomia Differentially Influences the Effect of Affective Pain Perception on Quality of Life in Parkinson's Disease Patients. 2016 , 2016, 3067426		1
153	Neurogenic orthostatic hypotension and supine hypertension in Parkinson's disease and related synucleinopathies: prioritisation of treatment targets. 2016 , 15, 954-966		78
152	Nonmotor features of Parkinson's disease subtypes. <i>Movement Disorders</i> , 2016 , 31, 1095-102	7	186
151	Orthostatic hypotension and cognitive impairment in Parkinson's disease: Causation or association?. <i>Movement Disorders</i> , 2016 , 31, 937-46	7	59
150	Nondopaminergic treatments for Parkinson's disease: current and future prospects. 2016 , 6, 249-68		29
149	Sensitive determination of neurotransmitters in urine by microchip electrophoresis with multiple-concentration approaches combining field-amplified and reversed-field stacking. 2016 , 1025, 33-9		15
148	Levodopa therapy for Parkinson disease: A look backward and forward. <i>Neurology</i> , 2016 , 86, S3-12	6.5	95
147	Neuropsychiatric Issues in Parkinson's Disease. 2016 , 16, 49		53
146	Cellular models for Parkinson's disease. 2016 , 139 Suppl 1, 121-130		62
145	Bradykinesia in early and advanced Parkinson's disease. 2016 , 369, 286-291		35
144	Emotional manifestations of PD: Neurobiological basis. <i>Movement Disorders</i> , 2016 , 31, 1103-13	7	54

143	Causes, consequences, and cures for neuroinflammation mediated via the locus coeruleus: noradrenergic signaling system. 2016 , 139 Suppl 2, 154-178		89
142	Effects of copper toxicity on response inhibition processes: a study in Wilson's disease. 2016 , 90, 1623-30		4
141	Non motor subtypes and Parkinson's disease. 2016 , 22 Suppl 1, S41-6		194
140	Pure autonomic failure versus prodromal dysautonomia in Parkinson's disease: Insights from the bedside. <i>Movement Disorders Clinical Practice</i> , 2017 , 4, 141-144	2.2	7
139	Cognitive Stress Reduces the Effect of Levodopa on Parkinson's Resting Tremor. 2017 , 23, 209-215		54
138	Paraquat and maneb co-exposure induces noradrenergic locus coeruleus neurodegeneration through NADPH oxidase-mediated microglial activation. 2017 , 380, 1-10		30
137	Targeting the norepinephrinergic system in Parkinson's disease and related disorders: The locus coeruleus story. <i>Neurochemistry International</i> , 2017 , 102, 22-32	4.4	70
136	Biomarkers of Parkinson's Disease: An Introduction. <i>International Review of Neurobiology</i> , 2017 , 132, 183-196	4.4	15
135	New Symptomatic Treatments for the Management of Motor and Nonmotor Symptoms of Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017 , 132, 407-452	4.4	4
134	ALCAR promote adult hippocampal neurogenesis by regulating cell-survival and cell death-related signals in rat model of Parkinson's disease like-phenotypes. <i>Neurochemistry International</i> , 2017 , 108, 388-396	4.4	12
133	Parkinson's: a syndrome rather than a disease?. <i>Journal of Neural Transmission</i> , 2017 , 124, 907-914	4.3	104
132	In vivo MRI assessment of the human locus coeruleus along its rostrocaudal extent in young and older adults. 2017 , 163, 150-159		63
131	Early clinical features of the parkinsonian-related dementias. 245-277		
130	Noradrenergic Dysfunction Could Contribute to Cognitive Impairments in Patients With Parkinson's Disease and REM Sleep Behavior Disorder. 2017 , 40,		
129	Nonmotor Subtyping in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017 , 133, 447-478	4.4	10
128	Presynaptic dopaminergic terminal imaging and non-motor symptoms assessment of Parkinson's disease: evidence for dopaminergic basis?. 2017 , 3, 5		23
127	Initiating droxidopa for neurogenic orthostatic hypotension in a patient with Parkinson disease. <i>Clinical Autonomic Research</i> , 2017 , 27, 13-14	4.3	7
126	Synucleinopathies: common features and hippocampal manifestations. 2017 , 74, 1485-1501		26

125	Current Nondopaminergic Therapeutic Options for Motor Symptoms of Parkinson's Disease. 2017 , 130, 1856-1866		11
124	Recent advances in treating Parkinson's disease. 2017 , 6, 260		74
123	Parkinson's Disease: From Pathogenesis to Pharmacogenomics. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	215
122	Role for Astroglial α -Adrenergic receptors in Glia-Neuron Communications and Aging-Related Metaplasticity in the Neocortex. 2017 , 81-102		
121	Long Road to Ruin: Noradrenergic Dysfunction in Neurodegenerative Disease. 2018 , 41, 211-223		102
120	Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies. <i>Movement Disorders</i> , 2018 , 33, 372-390	7	100
119	Clonidine modulates the activity of the subthalamic-supplementary motor loop: evidence from a pharmacological study combining deep brain stimulation and electroencephalography recordings in Parkinsonian patients. 2018 , 146, 333-347		10
118	Developmental Maturation and Alpha-1 Adrenergic Receptors-Mediated Gene Expression Changes in Ovine Middle Cerebral Arteries. <i>Scientific Reports</i> , 2018 , 8, 1772	4.9	2
117	Amperometric Determination of Catecholamines by Enzymatic Biosensors in Flow Systems. 2018 , 30, 1163-1171		8
116	Noradrenergic Modulation on Dopaminergic Neurons. 2018 , 34, 848-859		8
115	A case of multiple system atrophy-parkinsonian type with stuttering- and palilalia-like dysfluencies and putaminal atrophy. 2018 , 57, 51-58		1
114	Basic and Clinical Studies With Marine LipoFishins and Vegetal Favalins in Neurodegeneration and Age-Related Disorders. 2018 , 59, 195-225		5
113	A5 and A6 Noradrenergic Cell Groups: Implications for Cardiorespiratory Control. 2018 ,		
112	Microglia in Neurological Diseases: A Road Map to Brain-Disease Dependent-Inflammatory Response. 2018 , 12, 488		219
111	Longitudinal monoaminergic PET imaging of chronic proteasome inhibition in minipigs. <i>Scientific Reports</i> , 2018 , 8, 15715	4.9	7
110	Investigation of Behavioral Dysfunctions Induced by Monoamine Depletions in a Mouse Model of Parkinson's Disease. 2018 , 12, 241		19
109	Decreased noradrenaline transporter density in the motor cortex of Parkinson's disease patients. <i>Movement Disorders</i> , 2018 , 33, 1006-1010	7	19
108	Do Chemokines Have a Role in the Pathophysiology of Depression?. 2018 , 135-159		1

107	Palmitoylation as a Functional Regulator of Neurotransmitter Receptors. 2018 , 2018, 5701348		25
106	A53T- β synuclein overexpression in murine locus coeruleus induces Parkinson's disease-like pathology in neurons and glia. 2018 , 6, 39		29
105	Non-motor Parkinson disease: new concepts and personalised management. 2018 , 208, 404-409		45
104	Conversion of Astrocytes and Fibroblasts into Functional Noradrenergic Neurons. 2019 , 28, 682-697.e7		16
103	The locus coeruleus: Another vulnerability target in Parkinson's disease. <i>Movement Disorders</i> , 2019 , 34, 1423-1429	7	12
102	Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases. 2019 , 142, 2558-2571		109
101	Characterization of Motor and Non-Motor Behavioral Alterations in the Dj-1 (PARK7) Knockout Rat. 2019 , 69, 298-311		6
100	The Noradrenergic System. 2019 , 41-80		
99	Lesion of the Locus Coeruleus Damages Learning and Memory Performance in Paraquat and Maneb-induced Mouse Parkinson's Disease Model. 2019 , 419, 129-140		16
98	Metabolic response to Parkinson's disease recapitulated by the haploinsufficient diploid yeast cells hemizygous for the adrenodoxin reductase gene. 2019 , 15, 340-347		
97	Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders. <i>Journal of Neural Transmission</i> , 2019 , 126, 933-995	4-3	15
96	Norepinephrine-Fe(III)-ATP Ternary Complex and Its Relevance to Parkinson's Disease. 2019 , 10, 2777-2785		1
95	Recent Trends in the Quantification of Biogenic Amines in Biofluids as Biomarkers of Various Disorders: A Review. 2019 , 8,		13
94	DL-3-n-butylphthalide therapy for Parkinson's disease: A randomized controlled trial. 2019 , 17, 3800-3806		7
93	A Genetically Encoded Fluorescent Sensor for Rapid and Specific InVivo Detection of Norepinephrine. 2019 , 102, 745-761.e8		166
92	Circuit Mechanisms of Parkinson's Disease. 2019 , 101, 1042-1056		119
91	Stimulation of noradrenergic transmission by reboxetine is beneficial for a mouse model of progressive parkinsonism. <i>Scientific Reports</i> , 2019 , 9, 5262	4-9	17
90	Structural Influence and Interactive Binding Behavior of Dopamine and Norepinephrine on the Greek-Key-Like Core of β Synuclein Protofibril Revealed by Molecular Dynamics Simulations. 2019 , 7, 850		2

89	Optimization of Curcuminoids Extraction for Evaluation Against Parkinson's Disease in Rats. 2019 , 9, 335-351		1
88	Non-motor symptoms in early Parkinson's disease with different motor subtypes and their associations with quality of life. 2019 , 26, 400-406		38
87	Neural Correlates of Cognitive Impairment in Parkinson's Disease: A Review of Structural MRI Findings. <i>International Review of Neurobiology</i> , 2019 , 144, 1-28	4-4	17
86	PET imaging of noradrenaline transporters in Parkinson's disease: focus on scan time. 2019 , 33, 69-77		6
85	Noradrenergic pathways of locus coeruleus in Parkinson's and Alzheimer's pathology. 2020 , 130, 251-261		1
84	Tapentadol Prevents Motor Impairments in a Mouse Model of Dyskinesia. 2020 , 424, 58-71		2
83	Calcium-induced calcium release in noradrenergic neurons of the locus coeruleus. 2020 , 1729, 146627		1
82	Orthostatic Hypotension in Parkinson Disease. 2020 , 36, 53-67		23
81	Characterization of striatum-mediated behavior and neurochemistry in the DJ-1 knock-out rat model of Parkinson's disease. 2020 , 134, 104673		9
80	Identification of antiparkinsonian drugs in the 6-hydroxydopamine zebrafish model. 2020 , 189, 172828		9
79	A Dual Centre Study of Pain in Parkinson's Disease and Its Relationship with Other Non-Motor Symptoms. <i>Journal of Parkinson's Disease</i> , 2020 , 10, 1817-1825	5-3	7
78	Cognitive impairment in Parkinson's disease: A clinical and pathophysiological overview. 2020 , 419, 117177		7
77	Parkinson's disease and translational research. 2020 , 9, 43		7
76	Therapy of Parkinson's Disease Subtypes. 2020 , 17, 1366-1377		13
75	Non-Dopaminergic Treatments for Motor Control in Parkinson's Disease: An Update. 2020 , 34, 1025-1044		12
74	Orthostatic Hypotension Is Associated With Cognitive Decline in Parkinson Disease. 2020 , 11, 897		8
73	Non-Motor Symptoms of the Postural Instability and Gait Difficulty Subtype in De Novo Parkinson's Disease Patients: A Cross-Sectional Study in a Single Center. 2020 , 16, 2605-2612		5
72	Optimizing neuromelanin contrast in the substantia nigra and locus coeruleus using a magnetization transfer contrast prepared 3D gradient recalled echo sequence. 2020 , 218, 116935		6

71	Impaired Phasic Discharge of Locus Coeruleus Neurons Based on Persistent High Tonic Discharge-A New Hypothesis With Potential Implications for Neurodegenerative Diseases. 2020 , 11, 371		9
70	Integrin CD11b mediates locus coeruleus noradrenergic neurodegeneration in a mouse Parkinson's disease model. 2020 , 17, 148		12
69	Event-related potential changes due to early-onset Parkinson's disease in parkin (PARK2) gene mutation carriers and non-carriers. 2020 , 131, 1444-1452		3
68	Atomoxetine Does Not Improve Complex Attention in Idiopathic Parkinson's Disease Patients with Cognitive Deficits: A Meta-Analysis. 2020 , 2020, 4853590		1
67	MPTP-Induced Impairment of Cardiovascular Function. 2020 , 38, 27-37		8
66	Striatal Dopamine Denervation Impairs Gait Automaticity in Drug-Naïve Parkinson's Disease Patients. <i>Movement Disorders</i> , 2020 , 35, 1037-1045	7	6
65	Temporal development of neurochemical and cognitive impairments following reserpine administration in rats. <i>Behavioural Brain Research</i> , 2020 , 383, 112517	3-4	4
64	The Noradrenergic System in Parkinson's Disease. 2020 , 11, 435		22
63	Microglial CX3CR1 production increases in Alzheimer's disease and is regulated by noradrenaline. 2021 , 69, 73-90		9
62	Lack of Association of Locus Coeruleus Pathology with Orthostatic Hypotension in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2021 , 11, 233-237	5-3	1
61	The mechanistic link between selective vulnerability of the locus coeruleus and neurodegeneration in Alzheimer's disease. 2021 , 141, 631-650		19
60	Alzheimer's disease: An evolving understanding of noradrenergic involvement and the promising future of electroceutical therapies. <i>Clinical and Translational Medicine</i> , 2021 , 11, e397	5-7	8
59	Othello syndrome in Parkinson's disease: a systematic review and report of a case series. <i>Neurological Sciences</i> , 2021 , 42, 2721-2729	3-5	1
58	Parkinsonism-like disease induced by rotenone in rats: Treatment role of curcumin, dopamine agonist and adenosine A2A receptor antagonist. <i>Current Aging Science</i> , 2021 ,	2-2	1
57	Association of Locus Coeruleus and Substantia Nigra Pathology With Cognitive and Motor Functions in Patients With Parkinson Disease. <i>Neurology</i> , 2021 , 97, e1007-e1016	6-5	6
56	Rat Models of Vocal Deficits in Parkinson's Disease. <i>Brain Sciences</i> , 2021 , 11,	3-4	2
55	Locus Coeruleus Degeneration Correlated with Levodopa Resistance in Parkinson's Disease: A Retrospective Analysis. <i>Journal of Parkinson's Disease</i> , 2021 , 11, 1631-1640	5-3	1
54	Noninvasive vagus nerve stimulation in Parkinson's disease: current status and future prospects. <i>Expert Review of Medical Devices</i> , 2021 , 18, 971-984	3-5	0

53	The locus coeruleus shows a spatial pattern of structural disintegration in Parkinson's disease.		0
52	A Cross-Sectional Comprehensive Assessment of the Profile and Burden of Non-motor Symptoms in Relation to Motor Phenotype in the Nigeria Parkinson Disease Registry Cohort. <i>Movement Disorders Clinical Practice</i> , 2021 , 8, 1206-1215	2.2	0
51	Quantification of brainstem norepinephrine relative to vocal impairment and anxiety in the Pink1 ^{-/-} rat model of Parkinson disease. <i>Behavioural Brain Research</i> , 2021 , 414, 113514	3.4	2
50	Restoration of Noradrenergic Function in Parkinson's Disease Model Mice. <i>ASN Neuro</i> , 2021 , 13, 1759091-4211009730	5.3	1
49	A genetically encoded fluorescent sensor for rapid and specific in vivo detection of norepinephrine.		2
48	RBD, Antidepressant Medications, and Psychiatric Disorders. 2019 , 123-134		1
47	Metabolic response to Parkinson's disease recapitulated by the haploinsufficient phenotype of diploid yeast cells hemizygous for the adrenodoxin reductase gene.		
46	Calcium-induced calcium release in noradrenergic neurons of the locus coeruleus.		0
45	Manipulation of vocal communication and anxiety through pharmacologic modulation of norepinephrine in the Pink1 ^{-/-} rat model of Parkinson disease. <i>Behavioural Brain Research</i> , 2022 , 418, 113642	3.4	1
44	Cerebrospinal fluid biomarkers of Parkinson's disease: an update. 2020 , 345-363		
43	Therapeutic value of the metabolomic active neurotransmitter isorhynchophylline in the treatment of spontaneously hypertensive rats by regulating neurotransmitters. <i>Translational Neuroscience</i> , 2021 , 12, 425-431	1.2	
42	Droxidopa for the Treatment of Parkinson's Disease. 2020 , 1-9		
41	Locus coeruleus degeneration is associated with disorganized functional topology in Parkinson's disease. <i>NeuroImage: Clinical</i> , 2021 , 32, 102873	5.3	0
40	Comparisons of vesicular monoamine transporter type 2 signals in Parkinson's disease and parkinsonism secondary to carbon monoxide poisoning. <i>NeuroToxicology</i> , 2021 , 88, 178-186	4.4	1
39	Current concepts in treating mild cognitive impairment in Parkinson's disease. <i>Neuropharmacology</i> , 2022 , 203, 108880	5.5	0
38	Independent effect of neurogenic orthostatic hypotension on mild cognitive impairment in Parkinson's disease. <i>Clinical Autonomic Research</i> , 2021 , 1	4.3	1
37	Selected natural and synthetic agents effective against Parkinson's disease with diverse mechanisms. <i>Current Topics in Medicinal Chemistry</i> , 2021 ,	3	0
36	Genetic Pathways Involved in the Pathogenesis of Parkinson's Disease.. <i>Advances in Experimental Medicine and Biology</i> , 2021 , 1339, 195-208	3.6	

35	Cognition and serotonin in Parkinson's disease.. <i>Progress in Brain Research</i> , 2022 , 269, 373-403	2.9	0
34	Genetic lesions of the noradrenergic system trigger induction of oxidative stress and inflammation in the ventral midbrain.. <i>Neurochemistry International</i> , 2022 , 105302	4.4	0
33	Autonomic and Depression Symptoms in Parkinson's Disease: Clinical Evidence for Overlapping Physiology.. <i>Journal of Parkinson's Disease</i> , 2022 ,	5.3	0
32	Locus Coeruleus Shows a Spatial Pattern of Structural Disintegration in Parkinson's Disease.. <i>Movement Disorders</i> , 2022 ,	7	0
31	Parkinsons Disease-Like Neuropathology and Phenotype Following Induction of Oxidative Stress and Inflammation in the Brain. <i>Journal of Biomedical Research & Environmental Sciences</i> , 2022 , 3, 105-110 ^{0.3}		
30	Enhanced firing of locus coeruleus neurons and SK channel dysfunction are conserved in distinct models of prodromal Parkinson's disease.. <i>Scientific Reports</i> , 2022 , 12, 3180	4.9	0
29	The role of the locus coeruleus/norepinephrine system in the pathogenesis of neurodegenerative disorders: An update.. <i>Current Opinion in Neurology</i> , 2022 , 35,	7.1	
28	Respiratory Abnormalities in Parkinson's Disease: What Do We Know from Studies in Humans and Animal Models?. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	1
27	The Non-motor Symptoms, Disability Progression, and Survival Analysis of Atypical Parkinsonism: Case Series from Eastern India and Brief Review of Literature. <i>Journal of Neurosciences in Rural Practice</i> ,	1.1	
26	Table_1.docx. 2020 ,		
25	A Bioluminescent Probe for Detecting Norepinephrine .. <i>Analytical Chemistry</i> , 2022 ,	7.8	2
24	Social isolation, loneliness and mental health sequelae of the Covid-19 pandemic in Parkinson's disease. <i>International Review of Neurobiology</i> , 2022 ,	4.4	1
23	β-synuclein enfolds tyrosine hydroxylase and dopamine β-hydroxylase, potentially reducing dopamine and norepinephrine synthesis. <i>Journal of Proteins and Proteomics</i> ,	1.8	
22	Effect of Parkinson's Disease on Cardio-postural Coupling During Orthostatic Challenge. <i>Frontiers in Physiology</i> , 2022 , 13,	4.6	
21	Morphological basis of Parkinson disease-associated cognitive impairment: an update. <i>Journal of Neural Transmission</i> ,	4.3	1
20	Multiple N-of-1 trials to investigate hypoxia therapy in Parkinson's disease: study rationale and protocol. <i>BMC Neurology</i> , 2022 , 22,	3.1	0
19	Noradrenaline and Movement Initiation Disorders in Parkinson's Disease: A Pharmacological Functional MRI Study with Clonidine. 2022 , 11, 2640		0
18	The Neurodegenerative Elderly Syndrome (NES) hypothesis: Alzheimer and Parkinson are two faces of the same disease. 2022 ,		1

- 17 REM sleep behavior and olfactory dysfunction: improving the utility and translation of animal models in the search for neuroprotective therapies for Parkinson's disease. **2022**, 104897 ○
- 16 Behavioral and neurochemical interactions of the tricyclic antidepressant drug desipramine with L-DOPA in 6-OHDA-lesioned rats. Implications for motor and psychiatric functions in Parkinson's disease. ○
- 15 Systemic Metabolic Alteration Dependent on the Thyroid-Liver Axis in Early PD. ○
- 14 The role of neurotransmitter systems in mediating deep brain stimulation effects in Parkinson's disease. 16, ○
- 13 Droxidopa for the Treatment of Parkinson's Disease. **2022**, 3365-3373 ○
- 12 Disruption of Locus Coeruleus Related Functional Networks in Parkinson's Disease. ○
- 11 Assessing the association between white matter lesions and Parkinson's disease. ○
- 10 Cortical macro and microstructural correlates of cognitive and neuropsychiatric symptoms in Parkinson's disease. **2023**, 224, 107531 1
- 9 Targeting G protein-coupled receptors in the treatment of Parkinson's disease. **2022**, 167927 ○
- 8 Hallmarks of peripheral nerve function in bone regeneration. **2023**, 11, ○
- 7 Sleep and wakefulness disturbances in Parkinson's disease: A meta-analysis on prevalence and clinical aspects of REM sleep behavior disorder, excessive daytime sleepiness and insomnia. **2023**, 101759 ○
- 6 Neuromelanin magnetic resonance imaging of substantia nigra and locus coeruleus in Parkinson's disease with freezing of gait. 15, ○
- 5 Beyond shallow feelings of complex affect: Non-motor correlates of subjective emotional experience in Parkinson's disease. **2023**, 18, e0281959 ○
- 4 Pink1^{-/-} Rats Demonstrate Swallowing and Gastrointestinal Dysfunction in a Model of Prodromal Parkinson Disease. ○
- 3 Clinical features of minor hallucinations in different phenotypes of Parkinson's disease: A cross-sectional study. 14, ○
- 2 Comparative Study of Machine Learning Models for Early Detection of Parkinson's. **2023**, 51-69 ○
- 1 Structural and neurophysiological alterations in Parkinson's disease are aligned with cortical neurochemical systems. ○